Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Definitive Healthcare Corp (DH – Research Report), Anavex Life Sciences (AVXL – Research Report) and Inari Medical (NARI – Research Report).
Definitive Healthcare Corp (DH)
In a report issued on January 17, Kash Rangan from Goldman Sachs maintained a Hold rating on Definitive Healthcare Corp, with a price target of $9.50. The company’s shares closed last Monday at $9.11.
According to TipRanks.com, Rangan is a 5-star analyst with an average return of
Definitive Healthcare Corp has an analyst consensus of Moderate Buy, with a price target consensus of $9.61, representing a 7.3% upside. In a report issued on January 17, Barclays also upgraded the stock to Hold with a $10.00 price target.
See today’s best-performing stocks on TipRanks >>
Anavex Life Sciences (AVXL)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Anavex Life Sciences on January 18 and set a price target of $40.00. The company’s shares closed last Monday at $6.56.
According to TipRanks.com, Selvaraju is a 1-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Anavex Life Sciences with a $32.50 average price target.
Inari Medical (NARI)
In a report issued on January 17, Adam Maeder from Piper Sandler assigned a Buy rating to Inari Medical, with a price target of $85.00. The company’s shares closed last Monday at $56.64.
According to TipRanks.com, Maeder is a 5-star analyst with an average return of
Inari Medical has an analyst consensus of Strong Buy, with a price target consensus of $80.00, which is a 37.9% upside from current levels. In a report issued on January 11, Wells Fargo also maintained a Buy rating on the stock with a $100.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on DH:
- Definitive Healthcare downgraded to Hold from Buy at Needham
- Definitive Healthcare price target lowered to $11 from $12 at Stifel
- Definitive Healthcare price target lowered to $9 from $10 at Canaccord
- Definitive Healthcare sees FY24 revenue up 5%-7%, consensus $273.5M
- Definitive Healthcare Announces CEO Transition
